ArticleCureus2026
Comprehensive Genomic Profiling Across Diverse Tumors Using the OncoIndx® Assay: Real-World Insights From an Indian Cohort.
Article in Cureus, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background Comprehensive genomic profiling (CGP) enables the simultaneous detection of actionable genomic alterations and predictive biomarkers across diverse malignancies. However, real-world molecular oncology data from Indian populations remain limited. This study aimed to characterize the genomic landscape of diverse solid tumors using the OncoIndx® (OneCell Diagnostics India Pvt. Ltd., Mumbai, India) CGP platform within routine Indian clinical practice. Methods This retrospective single-center study included patients with histologically confirmed malignancies who underwent CGP testing between June 2022 and July 2025. Genomic profiling was performed using the OncoIndx® 1080-gene next-generation sequencing (NGS) platform, with analyses focused on mutation frequency, alteration type, pathway enrichment, clinical-actionability categorization, and exploratory biomarkers including microsatellite instability (MSI), tumor mutational burden (TMB), homologous recombination deficiency (HRD), programmed death-ligand 1 (PD-L1) expression, and circulating tumor DNA (ctDNA) tumor fraction. Results The cohort comprised 39 samples representing diverse solid tumors, predominantly gynecological, gastrointestinal, breast, central nervous system (CNS), and thoracic malignancies. A total of 124 genomic alterations involving 69 unique genes were identified in 33 patients, while six patients demonstrated no detectable genomic alterations. TP53 was the most frequently altered gene (43.6%), followed by PIK3CA (17.9%), ATM (10.3%), and KRAS (10.3%). Category-wise analysis demonstrated substantial clinical relevance, with Categories 1 and 2 collectively accounting for 47.6% of all detected alterations. Pathway enrichment analysis revealed predominant involvement of TP53/cell-cycle (24.2%), PI3K/AKT/mTOR (15.3%), DNA damage repair/HRD-homologous recombination repair (HRD-HRR) (12.9%), and RTK/RAS/MAPK signaling pathways (9.7%). Somatic mutation mapping demonstrated marked inter-patient molecular heterogeneity, encompassing missense mutations, amplifications, frameshift variants, splice-site alterations, and fusion events. Exploratory biomarker analysis revealed predominantly low MSI and low TMB, although isolated MSI-high, elevated TMB, and HRD-positive tumors were identified. Variable concordance between tissue biopsy- and liquid biopsy-based PD-L1 assessment further underscored underlying tumor heterogeneity. Conclusions This real-world Indian cohort demonstrated extensive genomic heterogeneity across diverse solid tumors, with recurrent alterations involving TP53/cell-cycle, PI3K/AKT/mTOR, DNA damage repair, and RTK/RAS/MAPK pathways. OncoIndx®-based CGP enabled the broad molecular characterization and identification of clinically relevant genomic alterations and exploratory biomarkers. These findings provide descriptive real-world molecular insights from an underrepresented Indian population and support further prospective evaluation of the clinical utility and outcome implications of CGP in Indian oncology practice.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.